Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?
作者信息
Perazella Mark A, Juncos Luis A
机构信息
Section of Nephrology, Yale School of Medicine, New Haven, Connecticut.
VA Connecticut Medical Center, West Haven, Connecticut.
出版信息
Kidney360. 2021 Dec 21;3(3):550-553. doi: 10.34067/KID.0007882021. eCollection 2022 Mar 31.
Abstract
摘要
相似文献
1
Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?药物性渗透性肾病：钠-葡萄糖协同转运蛋白2抑制剂也在其中？
Kidney360. 2021 Dec 21;3(3):550-553. doi: 10.34067/KID.0007882021. eCollection 2022 Mar 31.
2
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
3
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.血管紧张素 II 上调钠-葡萄糖协同转运蛋白 2 的表达，SGLT2 抑制剂可减轻血管紧张素 II 诱导的小鼠高血压肾损伤。
Clin Sci (Lond). 2021 Apr 16;135(7):943-961. doi: 10.1042/CS20210094.
4
Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.近端肾小管重吸收的变化通过 TGF 系统调节微血管调节。
Int J Mol Sci. 2022 Sep 23;23(19):11203. doi: 10.3390/ijms231911203.
5
Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.腺苷一磷酸活化蛋白激酶/沉默调节蛋白-1 激活和钠内流抑制的相互作用介导钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病中的肾脏获益：一个新的概念框架。
Diabetes Obes Metab. 2020 May;22(5):734-742. doi: 10.1111/dom.13961. Epub 2020 Feb 20.
6
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
7
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?SGLT2 抑制对人近端肾小管细胞的影响——在糖尿病肾病中的肾脏保护作用？
PLoS One. 2013;8(2):e54442. doi: 10.1371/journal.pone.0054442. Epub 2013 Feb 4.
8
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.重点更新：心力衰竭和/或慢性肾脏病患者的 SGLT2 抑制剂。
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
9
Development of SGLT1 and SGLT2 inhibitors.SGLT1 和 SGLT2 抑制剂的研发。
Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22.
10
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.
引用本文的文献
1
Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives.达格列净用于慢性肾脏病管理的临床评估：聚焦患者选择与临床视角
Int J Nephrol Renovasc Dis. 2022 Nov 1;15:289-308. doi: 10.2147/IJNRD.S234282. eCollection 2022.
2
Kidney-Protective Effects of SGLT2 Inhibitors.SGLT2 抑制剂的肾脏保护作用。
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):279-289. doi: 10.2215/CJN.09380822. Epub 2022 Oct 20.
3
A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium-Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study.钠-葡萄糖协同转运蛋白2抑制剂使用相关的急性肾衰竭和肾结石的描述：一项药物警戒数据库研究
Front Pharmacol. 2022 Aug 8;13:925805. doi: 10.3389/fphar.2022.925805. eCollection 2022.
Zotero 插件